Pharmacokinetics of oral versus intravenous ibuprofen for closure of patent ductus arteriosus: A pilot randomised controlled study.
| Autor: | Edison PE; Department of Neonatal & Developmental Medicine, The Academia, Singapore General Hospital, Singapore, Singapore., Chen S; Clinical Pharmacology Laboratory, Division of Cellular & Molecular Research, National Cancer Centre, Singapore General Hospital, Singapore, Singapore., Yeo CL; Department of Neonatal & Developmental Medicine, The Academia, Singapore General Hospital, Singapore, Singapore., Allen JC Jr; Centre for Quantitative Medicine, Office of Clinical Sciences, Duke NUS Medical School, Singapore, Singapore., Poon WB; Department of Neonatal & Developmental Medicine, The Academia, Singapore General Hospital, Singapore, Singapore., Baral VR; Department of Neonatal & Developmental Medicine, The Academia, Singapore General Hospital, Singapore, Singapore., Chowbay B; Clinical Pharmacology Laboratory, Division of Cellular & Molecular Research, National Cancer Centre, Singapore General Hospital, Singapore, Singapore.; Office of Clinical Sciences, Duke-NUS Medical School, Singapore, Singapore. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of paediatrics and child health [J Paediatr Child Health] 2022 Mar; Vol. 58 (3), pp. 397-403. Date of Electronic Publication: 2021 Sep 03. |
| DOI: | 10.1111/jpc.15720 |
| Abstrakt: | Aim: This pilot study aimed to compare the pharmacokinetic profiles of oral (PO) and intravenous (IV) ibuprofen for treatment of patent ductus arteriosus (PDA) in preterm neonates. Methods: In a single-centre, parallel, randomised open-label trial, neonates ≤35 weeks, weight <1800 g with haemodynamically significant PDA during the first week of life were recruited between June 2017 and February 2019 and randomised to receive either PO or IV ibuprofen at standard dosage of 10, 5 and 5 mg/kg every 24 h for three consecutive days. Plasma concentrations of ibuprofen were quantified using a validated high-performance liquid chromatography method and pharmacokinetic parameters were calculated. Treatment outcomes were recorded. Results: Eleven neonates participated in the trial, six and five patients receiving PO and IV ibuprofen, respectively. Pharmacokinetic analysis reveals similar ibuprofen exposure levels in treatment groups. Median dose- and weight-normalised C Conclusion: This exploratory study demonstrates comparable pharmacokinetics of PO and IV formulations of ibuprofen in preterm neonates. Larger prospective studies are required to validate these findings. (© 2021 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Plný text